The Unmet Need
For millions of women, endometriosis means years of chronic pelvic pain, fatigue, digestive problems, and the emotional toll of anxiety and depression, often dismissed or misdiagnosed for 7 to 10 years. When a diagnosis finally comes, the available treatments can only be prescribed for 12 months at a time due to serious side effects, including bone density loss and suicidal ideation.
1 in 10
Women of reproductive age live with endometriosis globally
7 to 10 years
Years average diagnostic delay from symptom onset
0
Approved oral treatments that address the disease without affecting fertility
Our Approach
Targeting the Root Cause, Not the Symptoms
Sur180 Therapeutics is pioneering a new direction by targeting the hypothalamic-pituitary-adrenal (HPA) axis, also known as the stress axis, rather than the traditional gonadal hormonal pathway.
Our research has identified that the corticotropin-releasing hormone receptor 1 (CRHR1) plays a fundamental role in inflammation, pain, and the development of endometriosis lesions. By blocking this receptor with a non-hormonal, orally available drug candidate, we aim to reduce pain, suppress inflammation within lesions, and reduce adhesions, without disrupting reproductive hormones or fertility.
By repositioning a molecule already known to be safe, Sur180 significantly reduces developmental costs compared to a novel compound. This translates into a more capital-efficient path to market and potential savings for health insurers and patients, increasing the commercial attractiveness of our approach.
Our Pipeline
Our Evidence
Built on Published, Peer-Reviewed Research
✓ Published in Biology of Reproduction, 2026
✓ Published in Disease and Therapeutics, 2026
✓ Supported by a competitive, peer-reviewed NIH grant
Built on 20+ years of translational research in neuroscience, gastroenterology, and molecular biology
Sur180 Therapeutics holds a granted U.S. patent with exclusive licensing rights and a second patent application under joint ownership, protecting our novel gynecologic use of this compound.
The Market Opportunity
A $180 to $220 Billion Global Market With No Solution Yet
$180B to $220B
Global market potential for endometriosis treatments
$1 trillion
Potential annual boost to the global economy from closing the women’s health gap by 2040
40× Return on Investment
Research shows a $350M investment in women’s health can generate $14B in value
Sur180 Therapeutics is positioned at the intersection of an unmet medical need, published peer-reviewed science, and a market that is finally being recognized. We are developing a non-hormonal oral treatment that targets the disease itself, can be used long term, and does not compromise fertility.
Who We Are
From Women, For Women
Sur180 Therapeutics is a women-centered biotech company built on more than 20 years of translational research by internationally recognized scientists in neuroscience, gastroenterology, and molecular biology. We are based in South Texas and Puerto Rico, and we are committed to developing therapies that give women real answers.
Our name tells our story. Sur, meaning “south” in Spanish, reflects the roots of our founding team and our base in South Texas and Puerto Rico. 180 speaks to our philosophy: real progress requires turning in a new direction. At Sur180, that is exactly what we are doing.
From left to right: Caroline B. Appleyard, Ph.D., Co-Founder & Scientific Director, Annelyn Torres-Reveron, Ph.D., Co-Founder & CEO, and Idhaliz Flores, Ph.D., Co-Founder & Chair of the Board.
